

around 55 years old),<sup>27</sup> although the mean age of this study was 50.6 years old. The number of aged patients with chronic hepatitis C is expected to increase in Europe and the USA, as well as in Japan. In IFN and ribavirin combination therapy, the discontinuance rate due to anemia was significantly higher in aged patients ( $\geq 60$  years old, 21%) than in younger patients ( $< 60$  years old, 9%) ( $P < 0.001$ ).<sup>25</sup> Earlier prediction of anemia is necessary to reduce the ribavirin dose in order to prevent the progression of severe anemia or to start epoetin alfa administration as needed, especially with aged patients. The “2 by 2” standard in PegIFN and ribavirin combination therapy should be a useful and convenient device for predicting the progress of anemia and treatment discontinuance in Europe and the USA, as well as in Japan.

## CONCLUSION

**I**N CONCLUSION, THIS paper has shown that the SVR rate can be raised by preventing the discontinuance of ribavirin in PegIFN and ribavirin combination therapy. What is now needed is a prospective study of whether the early reduction of ribavirin in “2 by 2” standard-positive patients can improve the SVR rates, to ascertain the utility of the “2 by 2” standard in PegIFN and ribavirin combination therapy.

## REFERENCES

- 1 Kasahara A, Hayashi N, Mochizuki K *et al.* Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology* 1998; 27: 1394–402.
- 2 Imai Y, Kasahara A, Tanaka H *et al.* Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. *J Gastroenterol* 2004; 39: 1069–77.
- 3 Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. *J Gastroenterol* 2006; 41: 17–27.
- 4 Poynard T, Marcellin P, Lee SS *et al.* Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet* 1998; 352: 1426–32.
- 5 McHutchison JG, Gordon SC, Schiff ER *et al.* Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med* 1998; 339: 1485–92.
- 6 Manns MP, McHutchison JG, Gordon SC *et al.* Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; 358: 958–65.
- 7 Fried MW, Shiffman ML, Reddy KR *et al.* Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975–82.
- 8 Hiramatsu N, Kasahara A, Nakanishi F *et al.* The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan. *Hepatol Res* 2004; 29: 142–7.
- 9 Bruno S, Camma C, Di Marco V *et al.* Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. *J Hepatol* 2004; 41: 474–81.
- 10 Hadziyannis SJ, Sette H Jr, Morgan TR *et al.* Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; 140: 346–55.
- 11 Berg T, Von Wagner M, Nasser S *et al.* Extended treatment duration for Hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130: 1086–97.
- 12 Lodato F, Azzaroli F, Brillanti S *et al.* Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. *J Viral Hepat* 2005; 12: 536–42.
- 13 Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. *Hepatology* 2005; 41: 275–9.
- 14 Bodenheimer HC Jr, Lindsay KL, Davis GL *et al.* Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. *Hepatology* 1997; 26: 473–7.
- 15 De Franceschi L, Fattovich G, Turrini F *et al.* Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. *Hepatology* 2000; 31: 997–1004.
- 16 Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G. Factors influencing ribavirin-induced hemolysis. *J Hepatol* 2001; 34: 911–16.
- 17 Tappero G, Ballare M, Farina M, Negro F. Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C. *J Hepatol* 1998; 29: 1033–4.
- 18 Afdhal NH, Dieterich DT, Pockros PJ *et al.* Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology* 2004; 126: 1302–11.
- 19 Pockros PJ, Shiffman ML, Schiff ER *et al.* Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. *Hepatology* 2004; 40: 1450–8.
- 20 Dieterich DT, Wasserman R, Brau N *et al.* Once-weekly epoetin alfa improves anemia and facilitates maintenance

- of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. *Am J Gastroenterol* 2003; 98: 2491-9.
- 21 Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. *J Viral Hepat* 2004; 11: 84-7.
- 22 Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. *Ther Drug Monit* 2000; 22: 555-65.
- 23 Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. *Am J Kidney Dis* 2004; 43: 140-6.
- 24 Karino Y, Kato T, Arakawa T *et al.* Total clearance (CL/F) of ribavirin is the factor most influencing the incidence of hemolytic anemia during IFN plus ribavirin therapy. *Hepatology* 2004; 40 (Suppl 1): 358.
- 25 Oze T, Hiramatsu N, Kurashige N *et al.* Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. *J Gastroenterol* 2006; 41: 862-72.
- 26 Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004; 39: 1147-67.
- 27 Hiramatsu N, Oze T, Tsuda N *et al.* Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? *Hepatol Res* 2006; 35: 185-9.

# Critical role of PA28 $\gamma$ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis

Kohji Moriishi\*, Rika Mochizuki\*, Kyoji Moriya<sup>†</sup>, Hironobu Miyamoto\*, Yoshio Mori\*, Takayuki Abe\*, Shigeo Murata<sup>‡</sup>, Keiji Tanaka<sup>§</sup>, Tatsuo Miyamura<sup>§</sup>, Tetsuro Suzuki<sup>§</sup>, Kazuhiko Koike<sup>‡</sup>, and Yoshiharu Matsuura\*<sup>¶</sup>

\*Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan; <sup>†</sup>Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan; <sup>‡</sup>Department of Molecular Oncology, Tokyo Metropolitan Institute of Medical Science, Tokyo 113-8613, Japan; and <sup>§</sup>Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan

Edited by Peter Palese, Mount Sinai School of Medicine, New York, NY, and approved December 1, 2006 (received for review August 23, 2006)

Hepatitis C virus (HCV) is a major cause of chronic liver disease that frequently leads to steatosis, cirrhosis, and eventually hepatocellular carcinoma (HCC). HCV core protein is not only a component of viral particles but also a multifunctional protein because liver steatosis and HCC are developed in HCV core gene-transgenic (CoreTg) mice. Proteasome activator PA28 $\gamma$ /REG $\gamma$  regulates host and viral proteins such as nuclear hormone receptors and HCV core protein. Here we show that a knockout of the PA28 $\gamma$  gene induces the accumulation of HCV core protein in the nucleus of hepatocytes of CoreTg mice and disrupts development of both hepatic steatosis and HCC. Furthermore, the genes related to fatty acid biosynthesis and *srebp-1c* promoter activity were up-regulated by HCV core protein in the cell line and the mouse liver in a PA28 $\gamma$ -dependent manner. Heterodimer composed of liver X receptor  $\alpha$  (LXR $\alpha$ ) and retinoid X receptor  $\alpha$  (RXR $\alpha$ ) is known to up-regulate *srebp-1c* promoter activity. Our data also show that HCV core protein enhances the binding of LXR $\alpha$ /RXR $\alpha$  to LXR-response element in the presence but not the absence of PA28 $\gamma$ . These findings suggest that PA28 $\gamma$  plays a crucial role in the development of liver pathology induced by HCV infection.

fatty acid | proteasome | sterol regulatory element-binding protein (SREBP) | RXR $\alpha$  | LXR $\alpha$

Hepatitis C virus (HCV) belongs to the Flaviviridae family, and it possesses a positive, single-stranded RNA genome that encodes a single polyprotein composed of  $\approx$ 3,000 aa. The HCV polyprotein is processed by host and viral proteases, resulting in 10 viral proteins. Viral structural proteins, including the capsid (core) protein and two envelope proteins, are located in the N-terminal one-third of the polyprotein, followed by nonstructural proteins.

HCV infects >170 million individuals worldwide, and then it causes liver disease, including hepatic steatosis, cirrhosis, and eventually hepatocellular carcinoma (HCC) (1). The prevalence of fatty infiltration in the livers of chronic hepatitis C patients has been reported to average  $\approx$ 50% (2, 3), which is higher than the percentage in patients infected with hepatitis B virus and other liver diseases. However, the precise functions of HCV proteins in the development of fatty liver remain unknown because of the lack of a system sufficient to investigate the pathogenesis of HCV. HCV core protein expression has been shown to induce lipid droplets in cell lines and hepatic steatosis and HCC in transgenic mice (4–6). These reports suggest that HCV core protein plays an important role in the development of various types of liver failure, including steatosis and HCC.

Recent reports suggest that lipid biosynthesis affects HCV replication (7–9). Involvement of a geranylgeranylated host protein, FBL2, in HCV replication through the interaction with NSSA suggests that the cholesterol biosynthesis pathway is also important for HCV replication (9). Increases in saturated and monounsaturated fatty acids enhance HCV RNA replication, whereas increases in polyunsaturated fatty acids suppress it (7). Lipid homeostasis is regulated by a family of steroid regulatory element-binding proteins (SREBPs), which activate the expression of >30 genes involved in

the synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids. Biosynthesis of cholesterol is regulated by SREBP-2, whereas that of fatty acids, triglycerides, and phospholipids is regulated by SREBP-1c (10–14). In chimpanzees, host genes involved in SREBP signaling are induced during the early stages of HCV infection (8). SREBP-1c regulates the transcription of acetyl-CoA carboxylase, fatty acid synthase, and stearoyl-CoA desaturase, leading to the production of saturated and monounsaturated fatty acids and triglycerides (15). SREBP-1c is transcriptionally regulated by liver X receptor (LXR)  $\alpha$  and retinoid X receptor (RXR)  $\alpha$ , which belong to a family of nuclear hormone receptors (15, 16). Accumulation of cellular fatty acids by HCV core protein is expected to be modulated by the SREBP-1c pathway because RXR $\alpha$  is activated by HCV core protein (17). However, it remains unknown whether HCV core protein regulates the *srebp-1c* promoter.

We previously reported (18) that HCV core protein specifically binds to the proteasome activator PA28 $\gamma$ /REG $\gamma$  in the nucleus and is degraded through a PA28 $\gamma$ -dependent pathway. PA28 $\gamma$  is well conserved from invertebrates to vertebrates, and amino acid sequences of human and murine PA28 $\gamma$ s are identical (19). The homologous proteins, PA28 $\alpha$  and PA28 $\beta$ , form a heteroheptamer in the cytoplasm, and they activate chymotrypsin-like peptidase activity of the 20S proteasome, whereas PA28 $\gamma$  forms a homoheptamer in the nucleus, and it enhances trypsin-like peptidase activity of 20S proteasome (20). Recently, Li and colleagues (21) reported that PA28 $\gamma$  binds to steroid receptor coactivator-3 (SRC-3) and enhances the degradation of SRC-3 in a ubiquitin- and ATP-independent manner. However, the precise physiological functions of PA28 $\gamma$  are largely unknown *in vivo*. In this work, we examine whether PA28 $\gamma$  is required for liver pathology induced by HCV core protein *in vivo*.

## Results

**PA28 $\gamma$ -Knockout HCV Core Gene Transgenic Mice.** To determine the role of PA28 $\gamma$  in HCV core-induced steatosis and the development of HCC *in vivo*, we prepared PA28 $\gamma$ -knockout core gene transgenic mice. The PA28 $\gamma$ -deficient, PA28 $\gamma$ <sup>-/-</sup> mice were born without

Author contributions: K. Moriishi, K.T., T.M., T.S., K.K., and Y. Matsuura designed research; K. Moriishi, R.M., K. Moriya, H.M., Y. Mori, and T.A. performed research; S.M. contributed new reagents/analytic tools; Y. Matsuura analyzed data; and K. Moriishi, K.K., and Y. Matsuura wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS direct submission.


Freely available online through the PNAS open access option.

Abbreviations: CoreTg, HCV core gene-transgenic; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LXR, liver X receptor; LXRE, liver X receptor-response element; MEF, mouse embryonic fibroblast; ROS, reactive oxygen species; RXR, retinoid X receptor; SRC-3, steroid receptor coactivator-3; SREBP, steroid regulatory element-binding protein.

<sup>¶</sup>To whom correspondence should be addressed. E-mail: matsuura@biken.osaka-u.ac.jp.

This article contains supporting information online at [www.pnas.org/cgi/content/full/0607312104/DC1](http://www.pnas.org/cgi/content/full/0607312104/DC1).


© 2007 by The National Academy of Sciences of the USA



**Fig. 1.** Preparation and characterization of PA28 $\gamma$ -knockout HCV core-transgenic mice. (A) The structures of the wild-type and mutated PA28 $\gamma$  genes and the transgene encoding the HCV core protein under the control of the HBV X promoter were investigated. Positions corresponding to the screening primers and sizes of PCR products are shown. PCR products of the HCV core gene as well as wild-type and mutated PA28 $\gamma$  alleles were amplified from the genomic DNAs of PA28 $\gamma^{+/+}$ , PA28 $\gamma^{+/+}$ CoreTg, PA28 $\gamma^{-/-}$ , and PA28 $\gamma^{-/-}$ CoreTg mice. (B) Body weights of PA28 $\gamma^{+/+}$ , PA28 $\gamma^{+/+}$ CoreTg, PA28 $\gamma^{-/-}$ CoreTg, and PA28 $\gamma^{-/-}$  mice at the age of 6 months. (C) HCV core protein levels in the livers of PA28 $\gamma^{+/+}$ CoreTg and PA28 $\gamma^{-/-}$ CoreTg mice were determined by ELISA (mean  $\pm$  SD,  $n = 10$ ). (D) Localization of HCV core protein in the liver. Liver sections of PA28 $\gamma^{+/+}$ , PA28 $\gamma^{+/+}$ CoreTg, and PA28 $\gamma^{-/-}$ CoreTg mice at the age of 2 months were stained with anti-HCV core antibody.

appreciable abnormalities in all tissues examined, with the exception of a slight retardation of growth (22). HCV core gene-transgenic (PA28 $\gamma^{+/+}$ CoreTg) mice were bred with PA28 $\gamma^{-/-}$  mice to create PA28 $\gamma^{+/+}$ CoreTg mice. The PA28 $\gamma^{+/+}$ CoreTg offspring were bred with each other, and PA28 $\gamma^{-/-}$ CoreTg mice were selected by PCR using primers specific to the target sequences (Fig. 1A). No significant differences in body weight were observed among the 6-month-old mice, although PA28 $\gamma^{-/-}$  mice exhibited a slight retardation of growth (Fig. 1B). A similar level of PA28 $\gamma$  expression was detected in PA28 $\gamma^{+/+}$ CoreTg and PA28 $\gamma^{+/+}$  mice (see Fig. 5B). The expression levels and molecular size of HCV core protein were similar in the livers of PA28 $\gamma^{+/+}$ CoreTg and PA28 $\gamma^{-/-}$ CoreTg mice (Fig. 1C; see also Fig. 5B).


**PA28 $\gamma$  Is Required for Degradation of HCV Core Protein in the Nucleus and Induction of Liver Steatosis.** HCV core protein has been detected at various sites, such as the endoplasmic reticulum, mitochondria, lipid droplets, and nucleus of cultured cell lines, as well as in hepatocytes of PA28 $\gamma^{+/+}$ CoreTg mice and hepatitis C patients



**Fig. 2.** Accumulation of lipid droplets by expression of HCV core protein. (A) Liver sections of the mice at the age of 6 months were stained with hematoxylin/eosin (HE). (B) (Upper) Liver sections of PA28 $\gamma^{+/+}$ CoreTg and PA28 $\gamma^{-/-}$ CoreTg mice at the age of 6 months were stained with oil red O. (Lower) The area occupied by lipid droplets of PA28 $\gamma^{+/+}$  (white), PA28 $\gamma^{+/+}$ CoreTg (gray), PA28 $\gamma^{-/-}$ CoreTg (black), and PA28 $\gamma^{-/-}$  (dark gray) mice was calculated by Image-Pro software (MediaCybernetics, Silver Spring, MD) (mean  $\pm$  SD,  $n = 10$ ).

(6, 23, 24). Although HCV core protein is predominantly detected in the cytoplasm of the liver cells of PA28 $\gamma^{+/+}$ CoreTg mice, as reported in ref. 6, in the present study a clear accumulation of HCV core protein was observed in the liver cell nuclei of PA28 $\gamma^{-/-}$ CoreTg mice (Fig. 1D). These findings clearly indicate that at least some fraction of the HCV core protein is translocated into the nucleus and is degraded through a PA28 $\gamma$ -dependent pathway. Mild vacuolation was observed in the cytoplasm of the liver cells of 4-month-old PA28 $\gamma^{+/+}$ CoreTg mice, and it became more severe at 6 months, as reported in ref. 25. Hematoxylin/eosin-stained liver sections of 6-month-old PA28 $\gamma^{+/+}$ CoreTg mice exhibited severe vacuolating lesions (Fig. 2A), which were clearly stained with oil red O (Fig. 2B Upper), whereas no such lesions were detected in the livers of PA28 $\gamma^{-/-}$ CoreTg, PA28 $\gamma^{+/+}$ , or PA28 $\gamma^{-/-}$  mice at the same age. The areas occupied by the lipid droplets in the PA28 $\gamma^{+/+}$ CoreTg mouse livers were  $\approx 10$  and 2–4 times larger than those of male and female of PA28 $\gamma^{+/+}$ , PA28 $\gamma^{-/-}$ , and PA28 $\gamma^{-/-}$ CoreTg mice, respectively (Fig. 2B Lower). These results suggest that PA28 $\gamma$  is required for the induction of liver steatosis by HCV core protein in mice.

**PA28 $\gamma$  Is Required for the Up-Regulation of SREBP-1c Transcription by HCV Core Protein in the Mouse Liver.** To clarify the effects of a knockout of the PA28 $\gamma$  gene in PA28 $\gamma^{+/+}$ CoreTg mice on lipid




**Fig. 3.** Transcription of genes regulating lipid biosynthesis in the mouse liver. (A) Total RNA was prepared from the livers of 2-month-old mice; and the transcription of genes encoding SREBP-1a, SREBP-1c, and SREBP-2 was determined by real-time PCR. (B) The transcription of genes encoding SREBP-1c, fatty acid synthase, acetyl-CoA carboxylase, stearyl-CoA desaturase, HMG-CoA synthase, and HMG-CoA reductase of 6-month-old mice was measured by real-time PCR. The transcription of the genes was normalized with that of hypoxanthine phosphoribosyltransferase, and the values are expressed as relative activity ( $n = 5$ ; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ). The transcription of each gene in PA28 $\gamma^{+/+}$ , PA28 $\gamma^{+/+}$ CoreTg, PA28 $\gamma^{-/-}$ CoreTg, and PA28 $\gamma^{-/-}$  mice is indicated by white, gray, black, and dark gray bars, respectively.

metabolism, genes related to the lipid biosyntheses were examined by real-time quantitative PCR. Transcription of SREBP-1c was higher in the livers of PA28 $\gamma^{+/+}$ CoreTg mice than in those of PA28 $\gamma^{+/+}$ , PA28 $\gamma^{-/-}$ , and PA28 $\gamma^{-/-}$ CoreTg mice at 2 months of age, but no such increases in SREBP-2 and SREBP-1a were observed (Fig. 3A). Although transcription of SREBP-1c and its regulating enzymes, such as acetyl-CoA carboxylase, fatty acid synthase, and stearyl-CoA desaturase, was also enhanced in the livers of 6-month-old PA28 $\gamma^{+/+}$ CoreTg mice compared with the levels in the livers of PA28 $\gamma^{+/+}$ , PA28 $\gamma^{-/-}$ , and PA28 $\gamma^{-/-}$ CoreTg mice, no statistically significant differences were observed with respect to the transcription levels of cholesterol biosynthesis-related genes that are regulated by SREBP-2 (e.g., HMG-CoA synthase and HMG-CoA reductase) (Fig. 3B). These results suggest the


following: (i) the up-regulation of SREBP-1c transcription in the livers of mice requires both HCV core protein and PA28 $\gamma$ ; and (ii) the nuclear accumulation of HCV core protein alone, which occurs because of the lack of degradation along a PA28 $\gamma$ -dependent proteasome pathway, does not activate the *srebp-1c* promoter.

**HCV Core Protein Indirectly Potentiates *srebp-1c* Promoter Activity in an LXR $\alpha$ /RXR $\alpha$ -Dependent Manner.** LXR $\alpha$ , which is primarily expressed in the liver, forms a complex with RXR $\alpha$  and synergistically potentiates *srebp-1c* promoter activity (16). Activation of RXR $\alpha$  by HCV core protein suggests that cellular fatty acid synthesis is modulated by the SREBP-1c pathway, although HCV core protein was not included in the transcription factor complex in the electrophoresis mobility shift assay (EMSA) (17). To analyze the effect of HCV core protein and PA28 $\gamma$  on the activation of the *srebp-1c* promoter, we first examined the effect of HCV core protein on the binding of the LXR $\alpha$ /RXR $\alpha$  complex to the LXR-response element (LXRE) located upstream of the SREBP-1c gene (Fig. 4A). Although a weak shift of the labeled LXRE probe was observed by incubation with nuclear extracts prepared from 293T cells expressing FLAG-tagged LXR $\alpha$  and HA-tagged RXR $\alpha$ , a clear shift was obtained by the treatment of cells with 9-*cis*-retinoic acid and 22(*R*)-hydroxycholesterol, ligands for LXR $\alpha$  and RXR $\alpha$ , respectively. In contrast, coexpression of HCV core protein with LXR $\alpha$  and RXR $\alpha$  potentiated the shift of the probe irrespective of the treatment with the ligands. Addition of 500 times the amount of nonlabeled LXRE probe (competitor) diminished the shift of the labeled probe induced by the ligands and/or HCV core protein. Furthermore, coinubation of the nuclear fraction with antibody to FLAG or HA tag but not with antibody to either HCV core or PA28 $\gamma$  caused a supershift of the labeled probe. These results indicate that HCV core protein does not participate in the LXR $\alpha$ /RXR $\alpha$ -LXRE complex but indirectly enhances the binding of LXR $\alpha$ /RXR $\alpha$  to the LXRE.

The activity of the *srebp-1c* promoter was enhanced by the expression of HCV core protein in 293T cells, and it was further enhanced by coexpression of LXR $\alpha$ /RXR $\alpha$  (Fig. 4B). Enhancement of the *srebp-1c* promoter by coexpression of HCV core protein and LXR $\alpha$ /RXR $\alpha$  was further potentiated by treatment with the ligands for LXR $\alpha$  and RXR $\alpha$ . The cells treated with 9-*cis*-retinoic acid exhibited more potent enhancement of the *srebp-1c* promoter than those treated with 22(*R*)-hydroxycholesterol. HCV core protein exhibited more potent enhancement of the *srebp-1c* promoter in cells treated with both ligands than in those treated with either ligand alone. These results suggest that HCV core protein poten-



**Fig. 4.** Activation of the *srebp-1c* promoter by HCV core protein. (A) FLAG-LXR $\alpha$  and HA-RXR $\alpha$  were expressed in 293T cells together with or without HCV core protein. Ligands for LXR $\alpha$  and RXR $\alpha$  dissolved in ethanol [Ligands (+)] or ethanol alone [Ligands (-)] were added to the culture supernatant at 24 h posttransfection. Cells were harvested at 48 h posttransfection, and nuclear extracts were mixed with the reaction buffer for EMSA in the presence or absence of antibody (100 ng) against HA, FLAG, HCV core or PA28 $\gamma$ , or nonlabeled LXRE probe (Competitor). (Left) The resulting mixtures were subjected to PAGE and blotted with horseradish peroxidase/streptavidin. The mobility shift of the LXRE probe and its supershift are indicated by a gray and black arrow, respectively. (Right) Expression of HCV core, HA-RXR $\alpha$ , FLAG-LXR $\alpha$ , and PA28 $\gamma$  in cells was detected by immunoblotting. (B) Effects of ligands for RXR $\alpha$ , 9-*cis*-retinoic acid (9cisRA), and for LXR $\alpha$ , 22(*R*)-hydroxycholesterol (22RHC), on the activation of the *srebp-1c* promoter in 293T cells expressing RXR $\alpha$ , LXR $\alpha$ , and/or HCV core protein. Ligands were added into the medium at a concentration of 5  $\mu$ M, and the cells were harvested after 24 h of incubation.



**Fig. 5.** PA28 $\gamma$  is required for HCV core-dependent activation of the *srebp-1c* promoter. (A) Effect of PA28 $\gamma$  knockdown on the LXR $\alpha$ /RXR $\alpha$ -DNA complex. FLAG-LXR $\alpha$  and HA-RXR $\alpha$  were expressed in FLC4 (control) or PA28 $\gamma$ -knockdown (PA28 $\gamma$ KD) cells together with or without HCV core protein. Cells were harvested at 48 h posttransfection, and nuclear extracts were mixed with the reaction buffer for EMSA. (Upper) The resulting mixtures were subjected to PAGE and blotted with horseradish peroxidase-streptavidin. The mobility shift of the LXRE probe is indicated by an arrow. (Lower) Expression of HCV core, HA-RXR $\alpha$ , FLAG-LXR $\alpha$ , and PA28 $\gamma$  in cells was detected by immunoblotting. (B) Effect of PA28 $\gamma$  knockout on the LXR $\alpha$ /RXR $\alpha$ -DNA complex in the mouse liver. (Upper) Nuclear extracts were prepared from the livers of 2-month-old PA28 $\gamma^{-/-}$ , PA28 $\gamma^{+/+}$ CoreTg, PA28 $\gamma^{-/-}$ CoreTg, and PA28 $\gamma^{+/+}$  mice and subjected to EMSA. The mobility shift of the LXRE probe is indicated by an arrow. (Lower) The expression of HCV core, PA28 $\gamma$ , and  $\beta$ -actin in the livers of the mice was detected by immunoblotting. (C) Effect of HCV core protein on *srebp-1c* promoter activity in PA28 $\gamma$ -knockout fibroblasts. A plasmid encoding firefly luciferase under the control of the *srebp-1c* promoter was transfected into MEFs prepared from PA28 $\gamma^{+/+}$  (Left) or PA28 $\gamma^{-/-}$  (Right) mice together with a plasmid encoding a *Renilla* luciferase. An empty plasmid or plasmids encoding mouse RXR $\alpha$  or LXR $\alpha$  were also cotransfected into the cells together with (gray bars) or without (white bars) a plasmid encoding HCV core protein. Luciferase activity under the control of the *srebp-1c* promoter was determined, and it is expressed as the fold increase in relative luciferase activity after standardization with the activity of *Renilla* luciferase.

tiates *srebp-1c* promoter activity in an LXR $\alpha$ /RXR $\alpha$ -dependent manner.

**HCV Core Protein Activates the *srebp-1c* Promoter in an LXR $\alpha$ /RXR $\alpha$ - and PA28 $\gamma$ -Dependent Manner.** To examine whether PA28 $\gamma$  is required for HCV core-induced enhancement of *srebp-1c* promoter activity in human liver cells, a PA28 $\gamma$ -knockdown human hepatoma cell line (FLC4 KD) was prepared. Enhancement of binding of the LXRE probe to LXR $\alpha$ /RXR $\alpha$  by coexpression of HCV core protein and LXR $\alpha$ /RXR $\alpha$  in FLC4 cells was diminished by knockdown of the PA28 $\gamma$  gene (Fig. 5A). Furthermore, formation of the LXR $\alpha$ /RXR $\alpha$ -LXRE complex was enhanced in the livers of PA28 $\gamma^{+/+}$ CoreTg mice but not in those of PA28 $\gamma^{-/-}$ , PA28 $\gamma^{-/-}$ , or PA28 $\gamma^{-/-}$ CoreTg mice (Fig. 5B). The expression of the HCV core protein in the mouse embryonic fibroblasts (MEFs) of PA28 $\gamma^{+/+}$  mice induced the activation of the mouse *srebp-1c* promoter through the endogenous expression of LXR $\alpha$  and RXR $\alpha$  (Fig. 5C Left). Further enhancement of the activation of the *srebp-1c* promoter by HCV core protein in PA28 $\gamma^{+/+}$  MEFs was achieved by the exogenous expression of both LXR $\alpha$  and RXR $\alpha$ . However, no enhancing effect of HCV core protein on *srebp-1c* promoter activity was observed in PA28 $\gamma^{-/-}$  MEFs (Fig. 5C Right). These results support the notion that HCV core protein enhances the activity of the *srebp-1c* promoter in an LXR $\alpha$ /RXR $\alpha$ - and PA28 $\gamma$ -dependent manner.

**Table 1.** HCC in mice at 16–18 months of age

Mouse and sex	Total no. of mice	No. of mice developing HCC	Incidence, %
PA28 $\gamma^{+/+}$ CoreTg			
Male	17	5	29.4
Female	28	3	10.7
PA28 $\gamma^{-/-}$			
Male	16	0	0
Female	4	0	0
PA28 $\gamma^{-/-}$ CoreTg			
Male	23	0	0
Female	13	0	0
PA28 $\gamma^{-/-}$ CoreTg			
Male	15	0	0
Female	21	0	0

**PA28 $\gamma$  Plays a Crucial Role in the Development of HCC in PA28 $\gamma^{+/+}$ CoreTg Mice.** The incidence of hepatic tumors in male PA28 $\gamma^{+/+}$ CoreTg mice older than 16 months was significantly higher than that in age-matched female PA28 $\gamma^{+/+}$ CoreTg mice (6). We reconfirmed here that the incidence of HCC in male and female PA28 $\gamma^{+/+}$ CoreTg mice at 16–18 months of age was 29.4% (5 of 17 mice) and 10.7% (3 of 28 mice), respectively. To our surprise, however, no HCC developed in PA28 $\gamma^{-/-}$ CoreTg mice (males, 15; females, 21), although, as expected, no HCC was observed in PA28 $\gamma^{+/+}$  (males, 16; females, 4) and PA28 $\gamma^{-/-}$  mice (males, 23; females, 13) (Table 1). These results clearly indicate that PA28 $\gamma$  plays an indispensable role in the development of HCC induced by HCV core protein.

## Discussion

HCV core protein is detected in the cytoplasm and partially in the nucleus and mitochondria of culture cells and hepatocytes of transgenic mice and hepatitis C patients (6, 23, 24, 26). Degradation of HCV core protein was enhanced by deletion of the C-terminal transmembrane region through a ubiquitin/proteasome-dependent pathway (27). We previously reported (18) that PA28 $\gamma$  binds directly to HCV core protein and then enhances degradation of HCV core protein in the nucleus through a proteasome-dependent pathway because HCV core protein was accumulated in nucleus of human cell line by treatment with proteasome inhibitor MG132. In this work, accumulation of HCV core protein was observed in nucleus of hepatocytes of PA28 $\gamma^{-/-}$ CoreTg mice (Fig. 1D). This result directly demonstrates that HCV core protein migrates into the nucleus and is degraded through a PA28 $\gamma$ -dependent pathway. However, HCV core protein accumulated in the nucleus because knockout of PA28 $\gamma$  gene abrogated the ability to cause liver pathology, suggesting that interaction of HCV core protein with PA28 $\gamma$  in the nucleus is prerequisite for the liver pathology induced by HCV core protein. We have previously shown (18) that HCV core protein is degraded through a PA28 $\gamma$ -dependent pathway, and Minami *et al.* (28) reported that PA28 $\gamma$  has a cochaperone activity with Hsp90. Therefore, degradation products of HCV core protein by means of PA28 $\gamma$ -dependent processing or correct folding of HCV core protein through cochaperone activity of PA28 $\gamma$  might be involved in the development of liver pathology. We do not know the reason why knockout of the PA28 $\gamma$  gene does not affect the total amount of HCV core protein in the liver of the transgenic mice. PA28 $\gamma$ -dependent degradation of HCV core protein may be independent of ubiquitination, as shown in SRC-3 (21), whereas knockdown of PA28 $\gamma$  in a human hepatoma cell line enhanced the ubiquitination of HCV core protein [supporting information (SI) Fig. 6], suggesting that lack of PA28 $\gamma$  suppresses a ubiquitin-independent degradation but enhances a ubiquitin-dependent degradation of HCV core protein. Therefore, the total amount of HCV

core protein in the liver of the mice may be unaffected by the knockout of the PA28 $\gamma$  gene.

Our results suggest that the interaction of HCV core protein with PA28 $\gamma$  leads to the activation of the *srebp-1c* promoter along an LXR $\alpha$ /RXR $\alpha$ -dependent pathway and the development of liver steatosis and HCC. HCV core protein was not included in the LXR $\alpha$ /RXR $\alpha$ -LXRE complex (Fig. 3A), suggesting that HCV core protein indirectly activates the *srebp-1c* promoter. Cytoplasmic HCV core protein was shown to interact with Sp110b, which is a transcriptional corepressor of RAR $\alpha$ -dependent transcription, and this interaction leads to the sequestering of Sp110b in the cytoplasm, resulting in the activation of RAR $\alpha$ -dependent transcription (29). The sequestration of an unidentified corepressor of the LXR $\alpha$ /RXR $\alpha$  heterodimer in the cytoplasm by HCV core protein may also contribute to the activation of the *srebp-1c* promoter. Although the precise physiological function of PA28 $\gamma$ -proteasome activity in the nucleus is not known, PA28 $\gamma$  has previously been shown (21) to regulate nuclear hormone receptors by means of the degradation of its coactivator SRC-3 and to participate in the fully Hsp90-dependent protein refolding (28). It appears reasonable to speculate that degradation or refolding of HCV core protein in a PA28 $\gamma$ -dependent pathway might be involved in the modulation of transcriptional regulators of various promoters, including the *srebp-1c* promoter. Saturated or monounsaturated fatty acids have been shown to enhance HCV RNA replication in Huh7 cells containing the full-length HCV replicon (7). The up-regulation of fatty acid biosynthesis by HCV core protein may also contribute to the efficient replication of HCV and to the progression of HCV pathogenesis.

Expression of HCV core protein was reported to enhance production of reactive oxygen species (ROS) (30), which leads to carbonylation of intracellular proteins (31). Enhancement of ROS production may trigger double-stranded DNA breaks and result in the development of HCC (30, 32, 33). HCV core protein could enhance the protein carbonylation in the liver of the transgenic mice in the presence but not in the absence of PA28 $\gamma$  (SI Fig. 7), suggesting that PA28 $\gamma$  is required for ROS production induced by HCV core protein. Development of HCC was observed in PA28 $\gamma^{+/+}$  CoreTg mice but not in PA28 $\gamma^{-/-}$  CoreTg mice (Table 1). Enhancement of ROS production by HCV core protein in the presence of PA28 $\gamma$  might be involved in the development of HCC in PA28 $\gamma^{+/+}$  CoreTg mice.

It is well known that resistant viruses readily emerge during the treatment with antiviral drugs targeting the viral protease or replicase, especially in the case of infection with RNA viruses. Therefore, antivirals targeting the host factors that are indispensable for the propagation of viruses might be an ideal target for the development of antiviral agents because of a lower rate of mutation than that of viral genome, if they have no side effects to patients. Importantly, the amino acid sequence of PA28 $\gamma$  of mice is identical to that of human, and mouse PA28 $\gamma$  is dispensable because PA28 $\gamma$  knockout mice exhibit no abnormal phenotype except for mild growth retardation. Therefore, PA28 $\gamma$  might be a promising target for an antiviral treatment of chronic hepatitis C with negligible side effects.

In summary, we observed that a knockout of the PA28 $\gamma$  gene from PA28 $\gamma^{+/+}$  CoreTg mice induced the accumulation of HCV core protein in the nucleus and disrupted the development of both steatosis and HCC. Activation of the *srebp-1c* promoter was up-regulated by HCV core protein both *in vitro* and *in vivo* through a PA28 $\gamma$ -dependent pathway, suggesting that PA28 $\gamma$  plays a crucial role in the development of liver pathology induced by HCV infection.

#### Materials and Methods

Histology and immunohistochemistry, real-time PCR, and detection of proteins modified by ROS are discussed in *SI Materials and Methods*.

**Plasmids and Reagents.** Human PA28 $\gamma$  cDNA was isolated from a human fetal brain library (18). The gene encoding HCV core protein was amplified from HCV strain J1 (genotype 1b) (34) and cloned into pCAG-GS (35). Mouse cDNAs of RXR $\alpha$  and LXR $\alpha$  were amplified by PCR from the total cDNAs of the mouse liver. The RXR $\alpha$  and LXR $\alpha$  genes were introduced into pEF-FLAGSpGBK (36) and pcDNA3.1 (Invitrogen, Carlsbad, CA), respectively. The targeting fragment for human PA28 $\gamma$  knockdown (GGATCCGGTGGATCAGGAAGTGAAGTTCAAGAGACTTCACTTCTGATCCACCTTTTTGGAAAAGCTT) was introduced into the BamHI and HindIII sites of pSilencer 4.1 U6 hyg vector (Ambion, Austin, TX). Mouse anti-FLAG (M2) and mouse anti- $\beta$ -actin antibodies were purchased from Sigma (St. Louis, MO). Rabbit polyclonal antibody against synthetic peptides corresponding to amino acids 70–85 of PA28 $\gamma$  was obtained from AFFINITI (Exeter, U.K.). Horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit IgGs were purchased from ICN Pharmaceuticals (Aurora, OH). Rabbit anti-HCV core protein was prepared by immunization with recombinant HCV core protein (amino acids 1–71), as described in ref. 24. Mouse monoclonal antibody to HCV core protein was kindly provided by S. Yagi (37). The plasmid for expression of HA-tagged ubiquitin was described in ref. 27.

**Preparation of PA28 $\gamma$ -Knockout HCV CoreTg Mice.** The generation of C57BL/6 mice carrying the gene encoding HCV core protein genotype 1b line C49 and that of PA28 $\gamma^{-/-}$  mice have been reported previously (22, 25). Both strains were crossbred with each other to create PA28 $\gamma^{-/-}$  CoreTg mice. PA28 $\gamma^{-/-}$  CoreTg mice were identified by PCR targeted at the PA28 $\gamma$  or HCV core gene (22, 25). Using 1  $\mu$ g of genomic DNA obtained from the mouse tail, the PA28 $\gamma$  gene was amplified by PCR with the following primers: sense, PA28-3 (AGGTGGATCAGGAAGTGAAGCTCAA); and antisense, PA28 $\gamma$ -5cr (CACCTCACTTGTGATCCGCTCTCTGAAAGAATCAACC). The targeted sequence for the PA28 $\gamma$ -knockout mouse was detected by PCR using the PA28-3 primer and the PAKO-4 primer (TGCAGTTCATTACAGGGCACCAGGACAG). The transgene encoding HCV core protein was detected by PCR as described in ref. 25. The expression of PA28 $\gamma$  and HCV core protein in the livers of 6-month-old mice was confirmed by Western blotting with mouse monoclonal antibody to HCV core protein, clone 11-10, and rabbit antibody to PA28 $\gamma$ . Mice were cared for according to the institutional guidelines. The mice were given ordinary feed, CRF-1 (Charles River Laboratories, Yokohama, Japan), and they were maintained under specific pathogen-free conditions.

All animal experiments conformed to the Guidelines for the Care and Use of Laboratory Animals, and they were approved by the Institutional Committee of Laboratory Animal Experimentation (Research Institute for Microbial Diseases, Osaka University).

**Preparation of Mouse Embryonic Fibroblasts.** MEFs were prepared as described in ref. 22. MEFs were cultured at 37°C under an atmosphere of 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% FBS, penicillin, streptomycin, sodium pyruvate, and nonessential amino acids.

**Transfection and Immunoblotting.** Plasmid vectors were transfected into the MEFs and 293T cells by liposome-mediated transfection by using Lipofectamine 2000 (Invitrogen). The amount of HCV core protein in the liver tissues was determined by an ELISA as described in ref. 37. The cell lysates were subjected to SDS/PAGE (12.5% gel), and they were then transferred onto PVDF membranes. Proteins on the membranes were treated with specific antibody and Super Signal Femto (Pierce, Rockford, IL). The results were then visualized by using an LAS3000 imaging system (Fuji Photo Film, Tokyo, Japan). The method of immunoprecipitation test is described in ref. 18.

**Reporter Assay for *srebp-1c* Promoter Activity.** The genomic DNA fragment encoding the *srebp-1c* promoter region (located from residues -410 to +24) was amplified from a mouse genome. The fragment was introduced into the KpnI and HindIII sites of pGL3-Basic (Promega, Madison, WI), and it was designated as pGL3-*srebp-1c*Pro. The plasmids encoding RXR $\alpha$  and LXR $\alpha$  were transfected into MEFs together with pGL3-*srebp-1c*Pro and a control plasmid encoding *Renilla* luciferase (Promega). The total DNA for transfection was normalized by the addition of empty plasmids. Cells were harvested at 24 h posttransfection. The ligand of RXR $\alpha$ , 9-*cis*-retinoic acid (Sigma), and that of LXR $\alpha$ , 22(*R*)-hydroxycholesterol (Sigma) were added at a final concentration of 5  $\mu$ M each to the culture medium of 293T cells transfected with pGL3-*srebp-1c*Pro together with expression plasmids encoding RXR $\alpha$ , LXR $\alpha$ , and HCV core protein at 24 h posttransfection. Cells were harvested 24 h after treatment. Luciferase activity was measured by using the dual-luciferase reporter assay system (Promega). Firefly luciferase activity was standardized with that of *Renilla* luciferase, and the results are expressed as the fold increase in relative luciferase units.

**Electrophoresis Mobility Shift Assay (EMSA).** EMSA was carried out by using a LightShift Chemiluminescent EMSA kit (Pierce) according to the manufacturer's protocol. Nuclear extract of the cell lines and liver tissue was prepared with an NE-PER nuclear

and cytoplasmic extraction reagent kit (Pierce). Briefly, double-stranded oligonucleotides for EMSA were prepared by annealing both strands of each LXRE of the *srebp-1c* promoter (5'-GGACGCCCGCTAGTAACCCCGG-3') (16). Both strands were labeled at the 5' ends with biotin. The annealed probe was incubated for 20 min on ice with nuclear extract (3  $\mu$ g of protein) in a reaction buffer containing 10 mM Tris-HCl (pH 7.5), 50 mM KCl, 1 mM DTT, 0.05  $\mu$ g/ $\mu$ l poly(dI-dC), 2.5% glycerol, 0.05% Nonidet P-40, and 0.1 nM labeled probe, with or without 1 mM nonlabeled probe. The resulting mixture was subjected to PAGE (5% gel) at 120 V for 30 min in 0.5 $\times$  TBE. The DNA-protein complex was transferred to a Hybond N+ membrane (Amersham, Piscataway, NJ), incubated with horseradish peroxidase-conjugated streptavidin, and visualized by using an LAS3000 imaging system.

**Statistical Analysis.** The results are expressed as the mean  $\pm$  SD. The significance of differences in the means was determined by Student's *t* test.

We thank H. Murase for secretarial work and D. C. S. Huang for providing the plasmids. This work was supported in part by grants-in-aid from the Ministry of Health, Labor, and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; the 21st Century Center of Excellence Program; and the Foundation for Biomedical Research and Innovation.

- Wasley A, Alter MJ (2000) *Semin Liver Dis* 20:1-16.
- Bach N, Thung SN, Schaffner F (1992) *Hepatology* 15:572-577.
- Lefkowitz JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC, Jr., Balart LA, Ortego TJ, Payne J, Dienstag JL, et al. (1993) *Gastroenterology* 104:595-603.
- Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C (1997) *Proc Natl Acad Sci USA* 94:1200-1205.
- Hope RG, McLauchlan J (2000) *J Gen Virol* 81:1913-1925.
- Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K (1998) *Nat Med* 4:1065-1067.
- Kapadia SB, Chisari FV (2005) *Proc Natl Acad Sci USA* 102:2561-2566.
- Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV (2002) *Proc Natl Acad Sci USA* 99:15669-15674.
- Wang C, Gale M, Jr, Keller BC, Huang H, Brown MS, Goldstein JL, Ye J (2005) *Mol Cell* 18:425-434.
- Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H (1998) *J Clin Invest* 101:2331-2339.
- Pai JT, Gurycy O, Brown MS, Goldstein JL (1998) *J Biol Chem* 273:26138-26148.
- Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL (1996) *J Clin Invest* 98:1575-1584.
- Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL (1997) *J Clin Invest* 99:846-854.
- Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD (1997) *J Clin Invest* 100:2115-2124.
- Repa JJ, Liang G, Ou J, Bashmakov Y, Lobbaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ (2000) *Genes Dev* 14:2819-2830.
- Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, et al. (2001) *Mol Cell Biol* 21:2991-3000.
- Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T (2002) *Hepatology* 35:937-946.
- Moriishi K, Okabayashi T, Nakai K, Moriya K, Koike K, Murata S, Chiba T, Tanaka K, Suzuki R, Suzuki T, et al. (2003) *J Virol* 77:10237-10249.
- Masson P, Andersson O, Petersen UM, Young P (2001) *J Biol Chem* 276:1383-1390.
- Li J, Rechsteiner M (2001) *Biochimie* 83:373-383.
- Li X, Lonard D, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai M, O'Malley BW (2006) *Cell* 124:381-392.
- Murata S, Kawahara H, Tohma S, Yamamoto K, Kasahara M, Nabeshima Y, Tanaka K, Chiba T (1999) *J Biol Chem* 274:38211-38215.
- Falcon V, Acosta-Rivero N, Chinae G, Gavilondo J, de la Rosa MC, Menendez I, Ducenas-Carrera S, Vina A, Garcia W, Gra B, et al. (2003) *Biochem Biophys Res Commun* 305:1085-1090.
- Suzuki R, Sakamoto S, Tsutsumi T, Rikimaru A, Tanaka K, Shimoike T, Moriishi K, Iwasaki T, Mizumoto K, Matsuura Y, et al. (2005) *J Virol* 79:1271-1281.
- Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K (1997) *J Gen Virol* 78:1527-1531.
- Yasui K, Wakita T, Tsukiyama-Kohara K, Funahashi SI, Ichikawa M, Kajita T, Moradpour D, Wands JR, Kohara M (1998) *J Virol* 72:6048-6055.
- Suzuki R, Tamura K, Li J, Ishii K, Matsuura Y, Miyamura T, Suzuki T (2001) *Virology* 280:301-309.
- Minami Y, Kawasaki II, Minami M, Tanahashi N, Tanaka K, Yahara I (2000) *J Biol Chem* 275:9055-9061.
- Watashi K, Hijikata M, Tagawa A, Doi T, Marusawa H, Shimotohno K (2003) *Mol Cell Biol* 23:7498-7509.
- Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM (2006) *J Virol* 80:7199-7207.
- Nystrom T (2005) *EMBO J* 24:1311-1317.
- Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr (1999) *Cell* 98:295-303.
- Carballo M, Conde M, El Bekay R, Martin-Nieto J, Camacho MJ, Monteseirin J, Conde J, Bedoya FJ, Sobrino F (1999) *J Biol Chem* 274:17580-17586.
- Aizaki H, Aoki Y, Harada T, Ishii K, Suzuki T, Nagamori S, Toda G, Matsuura Y, Miyamura T (1998) *Hepatology* 27:621-627.
- Niwa H, Yamamura K, Miyazaki J (1991) *Gene* 108:193-199.
- Huang DC, Cory S, Strasser A (1997) *Oncogene* 14:405-414.
- Aoyagi K, Ohuc C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S (1999) *J Clin Microbiol* 37:1802-1808.



## Hepatitis C Virus Nonstructural Protein 5A Modulates the Toll-Like Receptor-MyD88-Dependent Signaling Pathway in Macrophage Cell Lines<sup>∇</sup>

Takayuki Abe,<sup>1</sup> Yuuki Kaname,<sup>1</sup> Itsuki Hamamoto,<sup>1†</sup> Yoshimi Tsuda,<sup>1‡</sup> Xiaoyu Wen,<sup>1</sup> Shuhei Taguwa,<sup>1</sup> Kohji Moriishi,<sup>1</sup> Osamu Takeuchi,<sup>2</sup> Taro Kawai,<sup>2</sup> Tatsuya Kanto,<sup>3,4</sup> Norio Hayashi,<sup>3</sup> Shizuo Akira,<sup>2</sup> and Yoshiharu Matsuura<sup>1\*</sup>

*Department of Molecular Virology,<sup>1</sup> and Department of Host Defense,<sup>2</sup> Research Institute for Microbial Diseases, and Department of Gastroenterology and Hepatology,<sup>3</sup> and Department of Dendritic Cell Biology and Clinical Applications,<sup>4</sup> Graduate School of Medicine, Osaka University, Osaka, Japan*

Received 27 March 2007/Accepted 6 June 2007

Hepatitis C virus (HCV) infection induces a wide range of chronic liver injuries; however, the mechanism through which HCV evades the immune surveillance system remains obscure. Blood dendritic cells (DCs) play a pivotal role in the recognition of viral infection and the induction of innate and adaptive immune responses. Several reports suggest that HCV infection induces the dysfunction of DCs in patients with chronic hepatitis C. Toll-like receptor (TLR) has been shown to play various roles in many viral infections; however, the involvement of HCV proteins in the TLR signaling pathway has not yet been precisely elucidated. In this study, we established mouse macrophage cell lines stably expressing HCV proteins and determined the effect of HCV proteins on the TLR signaling pathways. Immune cells expressing NS3, NS3/4A, NS4B, or NS5A were found to inhibit the activation of the TLR2, TLR4, TLR7, and TLR9 signaling pathways. Various genotypes of NS5A bound to MyD88, a major adaptor molecule in TLR, inhibited the recruitment of interleukin-1 receptor-associated kinase 1 to MyD88, and impaired cytokine production in response to TLR ligands. Amino acid residues 240 to 280, previously identified as the interferon sensitivity-determining region (ISDR) in NS5A, interacted with the death domain of MyD88, and the expression of a mutant NS5A lacking the ISDR partially restored cytokine production. These results suggest that the expression of HCV proteins modulates the TLR signaling pathway in immune cells.

Hepatitis C virus (HCV) belongs to the family *Flaviviridae* and possesses a positive, single-stranded RNA genome that encodes a single polyprotein composed of approximately 3,000 amino acids. HCV polyprotein is processed by host and viral proteases, resulting in 10 viral proteins. Viral structural proteins, including the capsid protein and two envelope proteins, are located in the N-terminal one-third of the polyprotein, followed by nonstructural proteins. HCV infects 170 million people worldwide and frequently leads to cirrhosis and hepatocellular carcinoma (36). In over one-half of patients, acute infection evolves into a persistent carrier state, presumably due to the ability of HCV to incapacitate the activation of the host immune mechanisms. Dendritic cells (DCs) are one type of potent antigen-presenting cell in vivo and play a crucial role in the enhancement and regulation of cell-mediated immune reactions. Since DCs express various costimulatory and/or adhesion molecules, they can activate even naïve T cells in a primary response. The role of the response of HCV antigen-specific T cells in viral clearance or persistence has been in-

vestigated extensively in both humans and chimpanzees (6, 27, 48, 51). These studies suggest that acute HCV infections followed by viral clearance are associated with a high frequency of HCV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses that can persist (27, 51), while chronic HCV infections are characterized by weak and restricted CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses that are not sustained (51).

Toll-like receptors (TLRs) are membrane-bound receptors that can be activated by the binding of molecular structures conserved among families of microbes. More than 10 different TLRs have been identified to date (2). They are highly conserved among mammals and are expressed in a variety of cell types. TLR binding and stimulation by pathogen-associated molecules is followed by a cascade of intracellular events that culminate in the expression of multiple genes (2). TLR signaling is mediated primarily by the adaptor protein myeloid differentiation factor 88 (MyD88), which triggers the activation of transcription factors, such as NF- $\kappa$ B, that are essential for the expression of proinflammatory cytokine genes (2). This pathway also leads to the potent production of type I interferon (IFN) through the activation of IFN regulatory factor 7 (IRF7) upon stimulation of TLR7 or TLR9 (22). In contrast, Toll/interleukin-1 (IL-1) receptor homology domain-containing adaptor-inducing IFN- $\beta$  (TRIF/TICAM-1) mediates the production of type I IFNs primarily through the activation of IRF3 in response to TLR3 or TLR4 stimulation (2). Type I IFN induces the maturation of DCs by increasing both the expression of costimulatory molecules such as CD80, CD86, and CD40 and antigen presentation via major histocompatibility

\* Corresponding author. Mailing address: Research Center for Emerging Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan. Phone: 81-6-6879-8340. Fax: 81-6-6879-8269. E-mail: matsuura@biken.osaka-u.ac.jp.

† Present address: Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

‡ Present address: Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.

<sup>∇</sup> Published ahead of print on 13 June 2007.

complex class I in addition to classical endogenous antigen presentation; it also facilitates the cross-presentation of viral antigens. A cumulative report has shown that DC activation via TLR signaling is a prerequisite for the subsequent induction of vigorous T-cell responses (42). Some viral proteins have been shown to inhibit the TLR-dependent signaling pathway through interactions with the downstream adaptor molecules, suggesting that the alteration of TLR-mediated signals is one of the mechanisms of virus-induced immune modulation (49). Dysfunction of DCs in patients with chronic HCV infection due to immaturation caused by the direct infection of DCs by HCV or by interactions with HCV proteins has been reported previously (4, 21). On the other hand, there have also been contrasting reports suggesting a lack of impairment of DC function in both chimpanzees and humans chronically infected with HCV (26, 32). Thus, at present, alterations in the TLR signaling pathway in the immune cells of patients with chronic hepatitis C virus infection are not well understood.

In the present study, we examined the effect of HCV proteins on TLR function in murine macrophage cell lines stably expressing HCV proteins. The expression of NS3, NS3/4A, NS4B, or NS5A was found to impair the activation of the TLR signaling pathways, and NS5A interacted with MyD88 through the IFN sensitivity-determining region (ISDR) and impaired cytokine production. To the best of our knowledge, this is the first demonstration of NS5A as an immunomodulator of TLR signaling pathways through the direct interaction with an adaptor molecule in immune cells.

#### MATERIALS AND METHODS

**Cell culture.** Human embryonic kidney 293T cells and mouse macrophage RAW264.7 cells were maintained in Dulbecco's modified Eagle's medium (Sigma, St. Louis, MO) containing 10% fetal calf serum. All cells were cultured at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.

**Plasmids and viruses.** DNA fragments encoding each of the IICV structural and nonstructural proteins were generated from a full-length cDNA clone of genotype 1b strain J1 (1) by PCR using *Pfu* Turbo DNA polymerase (Stratagene, La Jolla, CA). The fragments were cloned into pCAGGs-puro/N-Flag, in which the sequence encoding a Flag tag is inserted at the 5' terminus of the cloning site of pCAGGs-puro (37). A protease-deficient NS3/4A mutant with Ser<sup>139</sup> replaced with Ala (S139A) was generated by the method of splicing by overlap extension and cloned into pCAGGs-puro. NS5A genes were amplified by PCR from HCV clones of strains of J1 (genotype 1b), H77c (genotype 1a, kindly provided by J. Bukh), and JFH1 (genotype 2a, kindly provided by T. Wakita) and cloned into pcDNA3.1Flag/IL4 (38). The NS5A deletion mutants were prepared as described previously (16). DNA fragments encoding a human MyD88, human Toll-IL-1 receptor domain-containing adapter protein (TIRAP), and human TRIF-related adaptor molecule (TRAM) were amplified by reverse transcription-PCR from total RNA of THP-1 cells and cloned into pcDNA3.1-C-Myc-His (Invitrogen, Carlsbad, CA) and pcDNA3.1Flag/HA. Murine IPS-1 (mIPS-1) was amplified from total RNA of RAW264.7 cells by reverse transcription-PCR and cloned into pcDNA3.1Flag/HA. Human MyD88 deletion mutants and a mIPS-1 mutant with Cys<sup>508</sup> replaced by Ala (C508A) were generated by the method of splicing by overlap extension and cloned into pcDNA3.1Flag/HA. pCMV1-RAK1-myc and pCMVIRAK4-myc, encoding IL-1 receptor-associated kinase 1 (IRAK-1) and IRAK-4, respectively, were prepared as described previously (53). pEFBossTICAM-I-HA was kindly provided by T. Seya (44). All PCR products were confirmed by sequencing by using an ABI PRISM 310 genetic analyzer (Applied Biosystems, Tokyo, Japan). Vesicular stomatitis virus (VSV) (Indiana strain, NCP12.1) (19) was kindly provided by M. A. Whitt.

**Establishment of stable cell lines expressing HCV proteins.** pCAGGs-puro/N-Flag plasmids encoding HCV proteins were transfected into RAW264.7 cells by liposome-mediated transfection using Lipofectamine 2000 (Invitrogen) and selected with 10 µg/ml of puromycin (InvivoGen, San Diego, CA). After about 2 to 3 weeks of selection, several clones were isolated, and cell lysates of each clone were immunoblotted with each of specific mouse anti-IICV antibody (1) or

anti-Flag M2 mouse monoclonal antibody (Sigma). Macrophage cell lines stably expressing HCV proteins and a control cell line obtained by transfection with an empty pCAGGs-puro vector were maintained in the presence of puromycin (10 µg/ml) throughout the experiments.

**Immunoprecipitation and immunoblotting.** Cells were seeded onto a six-well tissue culture plate 24 h before transfection. The plasmids were transfected by the lipofection method, and the cells were harvested at 48 h posttransfection, washed three times with 1 ml of ice-cold phosphate-buffered saline (PBS), and suspended in 0.4 ml lysis buffer containing 20 mM Tris-HCl (pH 7.4), 135 mM NaCl, 1% Triton X-100, 10% glycerol, and protease inhibitor cocktail tablets (Roche Molecular Biochemicals, Mannheim, Germany). Cell lysates were incubated for 30 min at 4°C and centrifuged at 14,000 × g for 15 min at 4°C. The supernatant was immunoprecipitated with 1 µg of mouse monoclonal anti-Flag M2, anti-hemagglutinin (1A) 16B12 (1A.11; BabCO, Richmond, CA), or anti-hexahistidine (Santa Cruz Biotechnology, Santa Cruz, CA) antibody and 10 µl of protein G-Sepharose 4B Fast Flow beads (Amersham Pharmacia Biotech, Franklin Lakes, NJ) at 4°C for 90 min. The immunocomplex was precipitated with the beads by centrifugation at 5,000 × g for 1 min and then washed five times with 0.4 ml of 20 mM Tris-HCl (pH 7.4) containing 135 mM NaCl and 0.05% Tween 20 (TBST buffer) by centrifugation. The proteins binding to the beads were boiled in 20 µl of sample buffer and then subjected to sodium dodecyl sulfate–12.5% polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore, Tokyo, Japan). The membranes were blocked with TBST containing 5% skim milk at room temperature for 1 h; incubated with mouse monoclonal anti-Flag M2, anti-1A 16B12, or anti-hexahistidine monoclonal antibody at room temperature for 1 h; and then incubated with horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG) antibody at room temperature for 1 h. The cell lines (2 × 10<sup>6</sup> cells/well) were stimulated with various doses of lipopolysaccharide (LPS) derived from *Salmonella enterica* serovar Minnesota (Re-595) (Sigma), peptidoglycans (PGN) derived from *Staphylococcus aureus* (Sigma), R-837 (InvivoGen), or phosphorothioate-stabilized mouse CpG (mCpG) oligodeoxynucleotides (ODN1668) (TCC-ATG-ACG-TTC-CTG-ATG-CT) (Invitrogen) for the times indicated, and the phosphorylation status of extracellular signal-regulated kinase (ERK) was determined by immunoblotting using antibodies specific to ERK1/2 or phosphorylated ERK1/2 (T202/Y204) (Cell Signaling Technology, Inc., Beverly, MA). Cells (1 × 10<sup>6</sup> cells/well) were treated with various doses of mouse IFN-α (PBL Biomedical Laboratories, New Brunswick, NJ) or VSV for 24 h, and the phosphorylation status of double-stranded RNA-dependent protein kinase (PKR) and signal transducer and activator of transcription 1 (STAT1) was determined by immunoblotting using antibodies specific to STAT1 (Cell Signaling), phosphorylated STAT1 (Cell Signaling), or phosphorylated PKR (BioSource International, Inc., Camarillo, CA). The immune complexes were visualized with Super Signal West Femto substrate (Pierce, Rockford, IL) and detected by using an LAS-3000 image analyzer system (FujiFilm, Tokyo, Japan).

**Cytokine production and enzyme-linked immunosorbent assay (ELISA).** To evaluate cytokine production in macrophage cell lines expressing HCV proteins, cells were seeded onto 96-well plates at a concentration of 1 × 10<sup>5</sup> cells/well and stimulated with various doses of LPS, PGN, R-837, or mCpG. After 24 h of incubation, culture supernatants were collected, and IL-6 production was determined by using an OptEIA mouse IL-6 set purchased from BD Pharmingen (San Diego, CA).

**Real-time PCR.** The cell lines (3 × 10<sup>6</sup> cells/well) were stimulated with R-837, LPS, PGN, mCpG, VSV, and polyinosine-poly(C) [poly(I:C)] (Invivogen) for the times indicated, and the expression of mRNA of cytokines, chemokines, and TLR genes was determined by real-time PCR. Total RNA was prepared from the macrophage cell lines using an RNeasy Mini kit (QIAGEN). First-strand cDNA was synthesized using a ReverTra Ace (TOYOBO, Japan) and oligo(dT)<sub>20</sub> primer. Each cDNA was estimated by Platinum SYBR Green qPCR SuperMix UDG (Invitrogen) according to the manufacturer's protocol. Fluorescent signals were analyzed by using an ABI PRISM 7000 apparatus (Applied Biosystems). Mouse Ccl2, IFN-β, IFN-α1, IFN-α4, and IL-1-α genes were amplified with primer pairs 5'-GCATCCACGTGTGGCTCA-3' and 5'-CTCCAGCCTACTCATTGGGATCA-3', 5'-ACACCAGCCTGGCTCCATC-3' and 5'-TTGGAGCTGGAGCTGCTTATAGTTG-3', 5'-AGCCTTGACACTCCGGTACAAATG-3' and 5'-TGGGTGAGCTCACTCAGGACA-3', 5'-GCTCAAGCCATCCTTGTGCTAA-3' and 5'-CATTGAGCTGATGGAGGTC-3', and 5'-TTGGTTAATGACCTGCAACAGGA-3' and 5'-AGGTCGGTCTCACTACCTGTGATG-3', respectively. The mouse TLR2, TLR3, TLR4, TLR7, TLR9, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) genes were amplified using primer pairs 5'-AGCCTTTGGCCTCTCIG-3' and 5'-AGAAC1GGGGGATATGC-3', 5'-AAATCCTTGGCTTGGCAAGTG-3' and 5'-TCAGTTGGGCGTTGTTCAAGAG-3', 5'-GCCTCGAATCCTGAGCAAACA-3' and 5'-CTTCTGCCC GGTAAGGTCCA-3', 5'-TCTGCAGGAGCTCTGCTTGA-3' and 5'-CAAGGCATGCTCAGTGGTGA-3', 5'-ACCAATGGCACCTGCCTAA-3' and 5'-




FIG. 1. Establishment of stable macrophage cell lines expressing HCV proteins. (A) Cell lysates were prepared from macrophage cell lines expressing each of the HCV proteins ( $4 \times 10^6$  cells) and immunoblotted with antibodies against HCV proteins or  $\beta$ -actin. (B) Total RNA was extracted from macrophage cell lines expressing NS5A (gray bars) or control (white bars), and the expression of mRNA of TLRs was determined by real-time PCR. (C) The subcellular localization of NS5A was examined by confocal microscopy. Cells were fixed with 4% paraformaldehyde-PBS, permeabilized with 0.5% Triton X-100, and stained with specific antibodies. Cells expressing NS5A or control cells were extracted into cytosol (C), membrane-organelle (M), and nuclear (N) fractions. Each fraction was concentrated and subjected to immunoblotting with specific antibodies. PA28 $\alpha$ , calregulin, and histone H1 were used as markers for cytosol, membrane-organelle, and nuclear fractions, respectively.

CGTCTTGAGAATGTTGTGGCTGA-3', and 5'-ACCACAGTCCATGCCATCAC-3' and 5'-TCCACCACCCTGTTGCTGTA-3', respectively. The expression of mRNAs of each of the chemokines, cytokines, and TLR was normalized with that of GAPDH mRNA.

**Immunofluorescence microscopy and subcellular localization of HCV proteins in stable macrophage cell lines.** Cells were seeded onto an eight-well chamber slide at  $1.5 \times 10^6$  cells per well, washed twice with PBS, fixed with PBS containing 4% paraformaldehyde at 18 h of cultivation, and permeabilized with PBS containing 0.5% Triton X-100 at 15 min. The cells were then incubated at 4°C for 1 h with 1  $\mu$ g of mouse anti-NS5A antibody (Austral Biologicals, San Ramon, CA) or rabbit polyclonal antibody against calregulin (Santa Cruz Biotechnology) in PBS containing 10% fetal calf serum (PBSF) and then incubated at room temperature for 1 h with 0.5  $\mu$ g of Alexa Fluor 488-conjugated anti-mouse IgG (Molecular Probes) or Alexa Fluor 594-conjugated anti-rabbit IgG (Molecular Probes) after three washes with PBSF. After extensive washing with PBSF, the samples were examined with a FluoView FV1000 laser scanning confocal microscope (Olympus, Japan). To confirm the subcellular localization of the HCV proteins in the macrophage cell lines, each stable cell line was fractionated with a Subcellular Proteome Extraction kit (Calbiochem, Darmstadt, Germany). Stepwise extraction resulted in four distinct fractions, which contained primarily cytosolic, membrane-organelle, nuclear, and cytoskeleton proteins, respectively. Each fraction was concentrated by Microcon (Millipore) and subjected to immunoblotting. PA28 $\alpha$  (Biomol International, Plymouth Meeting, PA), calregulin, and histone H1 (Santa Cruz Biotechnology) were used as cytoplasmic, membrane, and nuclear markers, respectively.

## RESULTS

**Establishment of macrophage cell lines stably expressing HCV proteins.** To examine the effect of HCV proteins on the TLR function of immune cells, we established murine macrophage cell lines stably expressing HCV structural or nonstructural proteins. We selected mouse macrophage RAW264.7 cells due to their high level of expression of various TLRs (3) and their high sensitivity to stimulation with TLR ligands. Processed HCV structural and nonstructural proteins were detected in each of the cell lines by immunoblot analyses using specific monoclonal antibodies (Fig. 1A). To examine the effect of HCV proteins on TLR expression in macrophage cell lines, the mRNA of TLRs in cells expressing NS5A was determined by real-time PCR (Fig. 1B). Although slight reductions in TLR2, TLR3, and TLR4 or enhancement of TLR7 and TLR9 was observed, a substantial amount of mRNA of the examined TLRs was detected in the cell lines expressing NS5A and other HCV proteins (data not shown). To determine the subcellular localization of HCV proteins in macrophage cell lines, the expression of HCV proteins was examined by con-




FIG. 2. Expression of HCV nonstructural proteins modulates IL-6 production and MAPK cascades through the TLR-dependent signaling pathway in macrophage cell lines. (A) Cells were seeded onto 96-well plates ( $1 \times 10^5$  cells/well) and stimulated with the indicated amounts of mCpG, R-837, LPS, or PGN. After 24 h of stimulation, IL-6 production in the culture supernatants was determined by sandwich ELISA. Data are shown as means  $\pm$  standard deviations (SD). (B) Cells ( $2 \times 10^6$  cells/well) were stimulated with  $10 \mu\text{g/ml}$  of R-837 for the times indicated, and ERK1/2 phosphorylation was determined by immunoblotting with antibodies to ERK and phosphorylated ERK (p-ERK). Asterisks indicate nonspecific bands. (C) Cells ( $2 \times 10^6$  cells/well) were stimulated with  $10 \mu\text{g/ml}$  of mCpG,  $25 \text{ ng/ml}$  of LPS, or  $10 \mu\text{g/ml}$  of PGN for the times indicated, and ERK1/2 phosphorylation was determined by immunoblotting.

focal microscopy and cell fractionation (Fig. 1C). HCV NS5A was colocalized with the endoplasmic reticulum marker cal-regulin in the macrophage cell line as reported previously for human hepatoma cell lines (47). Other HCV proteins exhibited similar localization with NS5A (data not shown). To further confirm the subcellular localization of NS5A proteins, cytoplasmic, membrane-organelle, and nuclear fractions of the cell line expressing NS5A were analyzed by Western blotting. NS5A was detected mainly in the membrane-organelle fraction.

**Expression of HCV NS3, NS3/4A, NS4B, or NS5A modulates the TLR-dependent signaling pathway in macrophage cell lines.** In order to determine the effect of the expression of HCV proteins on the TLR signaling pathway in macrophage cell lines, we examined the ability of HCV proteins to inhibit NF- $\kappa$ B activation via stimulation with various TLR ligands. The macrophage cell lines were stimulated with the TLR ligands, and the production of the proinflammatory cytokine IL-6 in the culture supernatants was determined by ELISA (Fig. 2A). The expression of HCV structural proteins or NS5B




FIG. 3. Effect of NS5A expression on the production of cytokines and chemokines in response to TLR ligands in macrophage cell lines. Cells ( $3 \times 10^6$  cells/well) were stimulated with 10  $\mu$ g/ml of mCpG, 10  $\mu$ g/ml of R-837, 25 ng/ml of LPS, and 10  $\mu$ g/ml of PGN for the times indicated. Total RNA was extracted from macrophage cell lines expressing NS5A (gray bars) or control (white bars), and the expression of mRNA of IL-1 $\alpha$  and Ccl2 (A) and IFN- $\beta$  and IL-6 (B) was determined by real-time PCR.

had no effect on IL-6 production after stimulation with mCpG, R-837, LPS, or PGN, which are ligands for TLR9, TLR7, TLR4, and TLR2, respectively. On the other hand, the expression of NS3, NS3/4A, NS4B, or NS5A inhibited the production of IL-6 induced by treatment with the ligands. These results indicate that the expression of NS3, NS3/4A, NS4B, and NS5A inhibits the production of IL-6 through the TLR-dependent signaling pathway in macrophage cell lines.

In addition to proinflammatory cytokine production via NF- $\kappa$ B activation, stimulation of TLR also activates mitogen-activated protein kinases (MAPKs). We then examined the activation of ERK, a MAPK signaling pathway, in response to the TLR ligands in the macrophage cells expressing HCV proteins (Fig. 2B). Although the expression of the HCV structural proteins NS3, NS4B, and NS5B did not alter the phosphorylation status of ERK1/2 in response to stimulation with the TLR7 ligand R-837, the expression of NS5A exhibited a clear inhibition of the phosphorylation of ERK1/2. To further examine the effect of NS5A expression on the MAPK cascade in response to the TLR ligands, the cells were treated with mCpG, LPS, and PGN. NS5A expression was found to inhibit the phosphorylation of ERK1/2 in response to stimulation with the ligands for TLR9, TLR4, and TLR2 (Fig. 2C). In contrast, the phosphorylation of c-Jun NH<sub>2</sub>-terminal kinase in

response to stimulation with R-837 was less impaired in the macrophage cell line expressing NS5A (data not shown). These results indicate that the expression of NS3, NS3/4A, NS4B, or NS5A inhibits the production of proinflammatory cytokines and that the expression of NS5A alone induces the inhibition of the MAPK cascade in response to stimulation by various TLR ligands in macrophage cells.

To further examine the effect of NS5A expression on the production of the other proinflammatory cytokines and chemokines in response to TLR ligands, the expression of mRNA of IL-1 $\alpha$  and Ccl2 in cells expressing NS5A after stimulation with TLR ligands was determined by real-time PCR (Fig. 3A). Expression of IL-1 $\alpha$  and Ccl2 was reduced in cells expressing NS5A by stimulation with mCpG, R-837, LPS, or PGN except for the IL-1 $\alpha$  expression by treatment with LPS, probably due to the TRIF-dependent activation of NF- $\kappa$ B. To further confirm the specific inhibition of the MyD88-dependent signaling pathway by NS5A, we examined the effects of NS5A expression in macrophage cells on the MyD88-independent/TRIF-dependent production of IFN- $\beta$  (Fig. 3B). Although the expression of IL-6 mRNA in cells expressing NS5A was impaired after stimulation with mCpG or LPS, the expression of IFN- $\beta$  was enhanced. These results suggest that the expression of NS5A specifically inhibits the MyD88-dependent signaling pathway.

**TLR-dependent and -independent immune activation of macrophage cells expressing NS3/4A or NS5A protein by RNA virus and dsRNA.** TLR3 has been shown to sensitize cells in response to double-stranded RNA (dsRNA) generated by viral infection and a synthetic dsRNA analog, poly(I:C), through an adaptor molecule, TRIF/TICAM-1, but not MyD88. Furthermore, RIG-I and MDA5 have been identified as being cytoplasmic dsRNA detectors responding to poly(I:C) and viral RNAs (57, 58), sensitizing cells through an adaptor molecule, IPS-1/MAVS/VISA/CARDIF, in a TLR-independent manner (24, 35, 46, 55). Recently, HCV NS3/4A protease was shown not only to cleave HCV nonstructural proteins but also to inhibit viral RNA- and dsRNA-induced IFN production through the cleavage of the adaptor molecules TRIF (28) and IPS-1 (29, 30, 33, 35). Moreover, it has been shown that NS3/4A protease inhibits dsRNA-induced immune activation in a protease-dependent manner in human hepatoma cell lines (11).

To determine whether murine TRIF (mTRIF) is cleaved by HCV NS3/4A protease, C-terminally His-tagged mTRIF was coexpressed with N-terminally Flag-tagged NS3, NS3/4A, or NS3/4A(S139A) in 293T cells. Immunoblot analyses revealed that mTRIF was not processed by HCV NS3/4A protease, probably due to differences in the amino acid sequences at the cleavage site in mTRIF (Fig. 4A). Amino acid sequences at the cleavage site of human TRIF are Cys<sup>372</sup> and Ser<sup>373</sup>, and those at the cleavage sites of mTRIF are Pro<sup>372</sup> and Ala<sup>373</sup> (Fig. 4B). These results suggest that HCV NS3/4A protease could not inhibit immune activation through the TLR3-mTRIF-dependent signaling pathway in murine cells. We next determined the processing of IPS-1 by HCV NS3/4A protease. N-terminally Flag-tagged mIPS-1 or its C508A mutant, with Cys<sup>508</sup> replaced with Ala to prevent cleavage by HCV NS3/4A protease, was coexpressed with N-terminally Flag-tagged NS3, NS3/4A, or NS3/4A(S139A) in 293T cells. Immunoblot analyses revealed that wild-type mIPS-1 was cleaved in cells coexpressing the active NS3/4A protease but not in those with NS3 (Fig. 4C). mIPS-1 processing was reduced in cells coexpressing NS3/4A(S139A) as well as in those coexpressing mIPS-1(C508A) and NS3/4A (Fig. 4C). Furthermore, we were able to detect cleavage of endogenous mIPS-1 in macrophage cell lines expressing NS3/4A but not in those expressing NS3 or NS3/4A(S139A) (Fig. 4D), indicating that mIPS-1 in murine macrophage cell lines is cleaved by HCV NS3/4A protease, as reported previously for a human hepatoma cell line.

We then examined the effect of expression of NS3/4A and NS5A on TLR-dependent and -independent immune activation induced by dsRNA. VSV and poly(I:C) were inoculated into macrophage cell lines, and the expression of mRNA of IFN- $\beta$  and IL-1 $\alpha$  was determined by real-time PCR (Fig. 4E). The macrophage cell lines expressing NS3/4A exhibited inhibition of IL-1 $\alpha$  and IFN- $\beta$  expression upon infection with VSV but not in response to poly(I:C), whereas no inhibition was observed in those expressing NS5A. These results suggest that the invasion of VSV and poly(I:C) is preferentially recognized in RAW cell lines by RIG-I-IPS-1- and TLR3-TRIF-dependent signaling pathways, respectively. Inhibition of IL-1 $\alpha$  and IFN- $\beta$  expression upon infection with VSV but not in response to poly(I:C) is probably due to the selective cleavage of IPS-1 but not TRIF by NS3/4A protease in the macrophage cell lines.

In contrast, the expression of NS5A has no effect on both TLR3-TRIF and RIG-I-IPS-1-dependent signaling pathways in macrophage cells.

Although MyD88/IRF7-dependent production of IFN- $\alpha$  upon activation was reported in plasmacytoid DCs (pDCs) (17, 23), it is unclear whether murine macrophage cells are capable of producing IFN- $\alpha$  in a TLR/MyD88/IRF7-dependent manner. To examine the effect of NS5A expression on IFN- $\alpha$  production, the expression of IFN- $\alpha$ 1 and IFN- $\alpha$ 4 in the macrophage cell line upon infection with VSV was determined (Fig. 4E, bottom). In contrast to the effect on IFN- $\beta$  production, the expression of NS5A in the macrophage cells reduced the production of IFN- $\alpha$ 1 and IFN- $\alpha$ 4 upon infection with VSV, although the inhibitory effect was weaker than that of NS3/4A. These results suggest that RAW264.7 cells are capable of producing IFN- $\alpha$  in a TLR/MyD88/IRF7-dependent manner upon infection with VSV as reported for pDCs, and the expression of NS5A partially counteracts this signaling pathway. However, the production of type I IFNs by the treatment with ligands for TLR7 (R-837) and TLR9 (mouse CpG) was weaker than that induced by infection with VSV in macrophage cells (data not shown). Further study is needed to clarify the precise mechanisms of the inhibition of TLR/MyD88/IRF7-dependent IFN- $\alpha$  production by the expression of HCV NS5A in human immune cells.

**NS5A interacts with MyD88 in mammalian cells.** The inhibition of the production of proinflammatory cytokines and chemokines and the MAPK cascade by NS5A expression in response to stimulation by various TLR ligands without participation of TRIF- and IPS-1-dependent signaling pathways suggests that NS5A specifically inhibits the TLR-MyD88-dependent signaling pathway in macrophage cell lines. MyD88 is a critical component of the signaling pathway and leads to the production of proinflammatory cytokines, chemokines, and MAPKs. To determine the effect of the expression of HCV proteins on the TLR signaling pathway in macrophage cell lines, the interaction of the HCV proteins with the adaptor molecules in the signaling pathway of the TLR family was examined by immunoprecipitation analysis. His-tagged MyD88 was coexpressed with Flag-tagged HCV proteins in 293T cells and immunoprecipitated with the indicated antibodies. As shown in Fig. 5A and B, MyD88 was coimmunoprecipitated with NS5A but not with structural and other nonstructural proteins in 293T cells.

To further confirm the specificity of the interaction of NS5A with MyD88, NS5A was coexpressed with other adaptor molecules in the TLR signaling pathway, TRAM, TIRAP, or TRIF, in 293T cells (Fig. 5C). NS5A interacted with MyD88 but not other adaptor molecules, suggesting that NS5A may inhibit the production of proinflammatory cytokines and chemokines and the phosphorylation of MAPKs through the counteraction of the MyD88-dependent TLR signaling pathway.

**NS5A interacts with the death domain of MyD88 through the ISDR and inhibits recruitment of IRAK to MyD88.** To determine the region of NS5A responsible for the interaction with MyD88, a series of deletion mutants of N-terminal Flag-tagged NS5A was constructed, and its interaction with His-tagged MyD88 was examined (Fig. 6A). The NS5A mutant covering amino acids 1 to 280 but not that covering amino




FIG. 4. TLR-dependent and -independent immune activation of macrophage cells expressing the NS3/4A or NS5A protein by RNA virus and dsRNA. (A) Myc-His-mTRIF was coexpressed with Flag-NS3, -NS3/4A, or -NS3/4A(S139A) in 293T cells and immunoblotted (IB) with antibodies against His and Flag. (B) Alignment of the flanking sequence of NS3 protease cleavage sites of NS4A/4B, NS4B/5A, TRIF, and IPS-1 of human and murine origins. The cleavage site is indicated by an arrow. (C) Flag-mIPS-1 and a mutant with Cys<sup>508</sup> replaced with Ala (C508A) were coexpressed with Flag-NS3, -NS3/4A, or -NS3/4A(S139A) in 293T cells and immunoblotted with antibodies against mIPS-1 and NS3. (D) Processing of endogenous mIPS-1. Cell lysates of the macrophage cell lines expressing NS3, NS3/4A, and NS3/4A(S139A) were immunoblotted with antibodies against mIPS-1, NS3, and  $\beta$ -actin. The cleavage product of mIPS-1 is indicated as mIPS-1\*. (E) Cells ( $3 \times 10^6$  cells/well) were stimulated with  $2 \times 10^5$  PFU/ml of VSV or 50  $\mu$ g/ml of poly(I:C) for the times indicated. Total RNA was extracted from the macrophage cell lines expressing NS3/4A (black bars), NS5A (gray bars), or control (white bars), and the expression of mRNA of IFN- $\beta$ , IL-1 $\alpha$ , IFN- $\alpha$ 1, and IFN- $\alpha$ 4 was determined by real-time PCR.




FIG. 5. NS5A interacts with MyD88. MyD88-His was coexpressed with Flag-core/E1/E2 or -NS5A (A) or Flag-NS3, -NS3/4A, -NS4B, -NS5A, or -NS5B (B) in 293T cells; immunoprecipitated (IP) with anti-Flag, E1, or E2 antibody; and immunoblotted (IB) with anti-His antibody. (C) Flag-NS5A was coexpressed with MyD88-His, TRAM-His, TIRAP-His, or TRIF-HA in 293T cells and immunoprecipitated with anti-His or -HA antibody. The immunoprecipitates were immunoblotted with anti-Flag antibody. Asterisks indicate nonspecific bands.

acids 1 to 200 exhibited binding to MyD88, suggesting that amino acid residues 200 to 280 of NS5A are required for the interaction with MyD88. Further mutational analyses of NS5A revealed that amino acid residues 240 to 280, which overlap the ISDR (amino acid residues 237 to 276), which was previously suggested to be involved in IFN resistance (10, 41), are required for the interaction with MyD88 (Fig. 6A). To determine the region of MyD88 responsible for the interaction with NS5A, His-tagged MyD88 mutants were coexpressed with Flag-tagged NS5A in 293T cells and immunoprecipitated with anti-His antibody. A MyD88 deletion mutant lacking amino acids 1 to 50, but not one lacking amino acids 1 to 80, and a mutant possessing amino acids 1 to 70 exhibited binding to NS5A, suggesting that amino acid residues 50 to 70 in the death domain of MyD88 are required for the interaction with NS5A (Fig. 6B).

MyD88 associates with TLRs and acts as an adapter that recruits IRAK, which is known as a key regulator for TLR7- and TLR9-mediated IFN- $\alpha$  production in pDCs (53). To determine the role of NS5A binding to MyD88 in the TLR-MyD88-dependent signaling pathway, we examined the association of IRAK with MyD88 in the presence of NS5A. Flag-tagged MyD88 was coexpressed with Myc-tagged IRAK-1 or IRAK-4 and immunoprecipitated with anti-Myc antibody (Fig. 6C, left). IRAK-1, but not IRAK-4, was coimmunoprecipitated with MyD88. Although NS5A did not bind to IRAK-1, it was not possible to assess the interaction of NS5A with IRAK-4 due to the degradation of NS5A in cells coexpressing IRAK-4 for unknown reasons (Fig. 6C, middle). To examine the interplay between IRAK-1 and MyD88 in the presence of NS5A, Flag-tagged MyD88 and Myc-tagged IRAK-1 were coexpressed with Flag-tagged NS5A in 293T cells. The interaction






FIG. 6. NS5A interacts with the death domain of MyD88 through the ISDR and inhibits recruitment of IRAK to MyD88. (A) The structure of NS5A and the MyD88 binding region are indicated at the top. MyD88-His was coexpressed with C-terminal deletion mutants of Flag-NS5A in 293T cells, immunoprecipitated (IP) with anti-His antibody, and immunoblotted (IB) with anti-Flag antibody (left). MyD88-His was coexpressed with Flag-NS5A deletion mutants ( $\Delta$ 240-280 or  $\Delta$ 280-300) in 293T cells, immunoprecipitated with anti-Flag antibody, and then immunoblotted with anti-His antibody (right). (B) Flag-NS5A was coexpressed with N-terminal or C-terminal deletion mutants of MyD88-His ( $\Delta$ N1,  $\Delta$ N2,  $\Delta$ N3,  $\Delta$ C1,  $\Delta$ C2, or  $\Delta$ C3) in 293T cells, immunoprecipitated with anti-His antibody, and immunoblotted with anti-Flag antibody. The structures of MyD88 and the deletion mutants and the NS5A binding region are indicated on the right. (C) Flag-MyD88 (left) or Flag-NS5A (middle) was coexpressed with IRAK-1-Myc or IRAK-4-Myc in 293T cells, immunoprecipitated with anti-Myc antibody, and immunoblotted with anti-Flag antibody. Flag-MyD88 and IRAK-1-Myc were coexpressed with Flag-NS5A in 293T cells, immunoprecipitated with anti-Myc antibody, and immunoblotted with anti-Flag antibody. The effect of the increase in Flag-NS5A expression on the interaction of MyD88 with IRAK-1 was examined by transfection with 0.1, 0.5, or 2  $\mu$ g of Flag-NS5A expression plasmid (right).




FIG. 7. NS5A of other genotypes also interacts with MyD88 and inhibits the TLR signaling pathway. (A) Flag-NS5As of other genotypes were coexpressed with MyD88-His in 293T cells, immunoprecipitated (IP) with anti-Flag antibody, and immunoblotted (IB) with anti-His antibody. (B) The wild type or a deletion mutant lacking amino acids 240 to 280 of Flag-NS5A of genotype 1a or 2a was coexpressed with MyD88-His in 293T cells, immunoprecipitated with anti-Flag antibody, and immunoblotted with anti-His antibody. (C) Amino acid sequences of ISDR and its adjacent region of strains H77c (genotype 1a), J1 (genotype 1b), Con1 (genotype 1b), and JFH1 (genotype 2a). The conserved amino acids among genotypes 1a and 1b are indicated by boxes. Conserved amino acids among all strains are indicated by asterisks. (D) Macrophage cell lines expressing NS5A of genotypes 1a (H77c), 1b (J1), and 2a (JFH1) were established. Cells were stimulated with the indicated amounts of mCpG, R-837, LPS, or PGN, and the production of IL-6 in the culture supernatants was determined by ELISA 24 h after stimulation. Data are shown as the means  $\pm$  SD.

of IRAK-1 and MyD88 decreased in accord with the increasing NS5A expression complex (Fig. 6C, right), suggesting that the expression of NS5A may interfere with the TLR-MyD88-dependent signaling pathway through the inhibition of the recruitment of IRAK-1 to MyD88.

NS5A of other genotypes also interacts with MyD88 and inhibits the TLR signaling pathway. To determine the interaction of MyD88 with NS5A of other genotypes, Flag-tagged NS5A of genotype 1a (H77c) or 2a (JFH1) was coexpressed with His-tagged MyD88 in 293T cells. MyD88 was coprecipitated with the NS5As of genotypes 1a and 2a, although it should be noted that the interaction between the MyD88 and NS5A of genotype 2a was weaker than that of the other genotypes (Fig. 7A). To determine the region of the NS5As of genotype 1a or 2a responsible for the interaction with MyD88, N-terminal Flag-tagged NS5As of genotype 1a or 2a deletion

mutants lacking amino acids 240 to 280 ( $\Delta$ 240-280) were constructed, and their interaction with MyD88 was examined. Mutational analyses revealed that amino acid residues 240 to 280 of the NS5As of genotypes 1a and 2a were also required for the interaction with MyD88 (Fig. 7B). Amino acid alignment of the ISDRs of genotypes 1a, 1b, and 2a revealed that the region of genotype 2a was less conserved than those of the other genotypes (Fig. 7C).

To determine the effect of NS5A expression of other genotypes on the TLR signaling pathway, we established macrophage cell lines expressing NS5A of each genotype. NS5A expression for all genotypes was found to inhibit IL-6 production after stimulation with mCpG, R-837, LPS, or PGN (Fig. 7D). Although the association of NS5A of genotype 2a to MyD88 was weaker than that of other genotypes, the expression of genotype 2a NS5A in macrophage cells exhibited com-




FIG. 8. ISDR in NS5A participates in the inhibition of the MyD88-dependent signaling pathway. (A) Structures of NS5A mutants lacking amino acid residues 240 to 280, in which the ISDR/MyD88-interacting region is located ( $\Delta 240-280$ ), and lacking amino acid residues 280 to 300 ( $\Delta 280-300$ ) (left). Immunoblot analyses of cells expressing wild-type or mutant NS5A (right) are shown. (B) Cells expressing wild-type or mutant NS5A were stimulated with the indicated amounts of mCpG, R-837, LPS, or PGN, and the production of IL-6 in the culture supernatants was determined by ELISA 24 h after stimulation. Data are shown as the means  $\pm$  SD. (C) Phosphorylation of STAT1 or PKR in response to treatment with murine IFN- $\alpha$  or infection with VSV. The cell lines were stimulated with two doses of murine IFN- $\alpha$  ( $2 \times 10^3$  and  $2 \times 10^5$  units/ml) or VSV ( $2 \times 10^7$  and  $2 \times 10^6$  PFU/ml). After 24 h of stimulation, cell extracts were immunoblotted (IB) with specific antibodies. Phosphorylated STAT1 and PKR and the total amounts of STAT1 and  $\beta$ -actin were determined. The asterisk indicates nonspecific bands.

parable inhibition of IL-6 production in response to stimulation by various TLR ligands with those of genotypes 1b and 1a. These results suggest that NS5As of genotypes 1a, 1b, and 2a interact with MyD88 and inhibit the TLR signaling pathway in macrophage cell lines.

**ISDR participates in the inhibition of the MyD88-dependent signaling pathway by NS5A.** To further confirm the inhibitory effect of NS5A on the TLR signaling pathway, we established macrophage cell lines stably expressing an NS5A mutant lacking the ISDR/MyD88 binding region ( $\Delta 240-280$ ) or lacking a region dispensable for the interaction with MyD88 ( $\Delta 280-300$ ) (Fig. 8A). The inhibitory effect of TLR signaling in response to

stimulation with mCpG, R-837, LPS, or PGN by NS5A was partially restored in the cell line expressing the NS5A lacking the ISDR ( $\Delta 240-280$ ), and comparable inhibition was observed in the cell line expressing the NS5A deletion mutant retaining the ISDR ( $\Delta 280-300$ ) (Fig. 8B). These results suggest that the interaction of NS5A with MyD88 through the ISDR is responsible for the disruption of the TLR-MyD88-dependent signaling pathway due to the expression of NS5A in macrophage cells. Partial recovery of the TLR signaling pathway by the expression of the NS5A mutant lacking the ISDR suggests the involvement of other inhibitory mechanisms by NS5A.

Previous reports suggested that the ISDR of NS5A participates in conferring IFN sensitivity (10) and in an interaction with PKR (13). To determine the effect of the interaction of MyD88 with NS5A through the ISDR on the IFN signaling pathway, we examined the phosphorylation of STAT1 and PKR in response to treatment with murine IFN- $\alpha$  and infection with VSV. The expression of wild-type NS5A and the  $\Delta$ 280–300 mutant but not the  $\Delta$ 240–280 mutant reduced the phosphorylation of STAT1 in response to IFN- $\alpha$  treatment (Fig. 8C, top), suggesting that the ISDR/MyD88 binding region in NS5A is involved in the IFN signaling pathway. Although cells expressing wild-type NS5A reduced PKR phosphorylation, those expressing mutant NS5A ( $\Delta$ 240–280 or  $\Delta$ 280–300) did not inhibit PKR phosphorylation upon infection with VSV (Fig. 8C, bottom), which is consistent with the previous observation that the 66 ISDR-inclusive amino acid residues (amino acids 237 to 302) are required for interactions with PKR (13). These results suggest that the expression of HCV NS5A in macrophage cells counteracts the IFN signaling pathway through the repression of STAT1 and PKR due to the interaction with ISDR and its adjacent region.

### DISCUSSION

The majority of HCV-infected individuals become chronic carriers; however, the mechanism of progression to chronicity remains unclear. Among HCV proteins, NS3 has been shown to be immunodominant, and T cells that are reactive to NS3 have been suggested to play a crucial role in viral clearance, while HCV core protein is immunosuppressive (8). Treatment of immature DCs with core or NS3 protein inhibited DC differentiation, and DCs transduced to express core or E1 protein exhibited poor allogeneic T-cell responses (43). The immunosuppressive potential of HCV proteins has been implicated as a mechanism of the functional subversion of T cells, natural killer (NK) cells, and DCs. The association of HCV core protein with the globular domain of the C1q receptor on T cells down-regulates T-cell proliferation and IL-2 production (25). Additionally, the HCV E2 protein displays a high affinity for the tetraspanin cell surface molecule human CD81, which is one of the candidates for an HCV entry receptor (40), and E2 cross-linking with cell surface human CD81 impairs the activation of NK cells (7, 52).

In the present study, we established macrophage cell lines stably expressing HCV proteins and examined the effects of viral proteins on TLR function. The expression of the NS5A protein specifically inhibits TLR-MyD88-induced signaling by associating with the death domain of MyD88 through the ISDR spanning amino acid residues 240 to 280 in macrophage cells. HCV NS5A is a phosphoprotein that appears to possess multiple and diverse functions in viral replication, IFN resistance, and pathogenesis (34). Mutation in the ISDR has been suggested to correlate with the responsiveness of patients chronically infected with HCV genotype 1b to IFN treatment (10). Furthermore, NS5A has been shown to rescue virus replication in IFN-treated cell cultures (41) and to inhibit the antiviral activity of IFN by binding to PKR through the ISDR and its adjacent region (amino acids 237 to 302) (13, 14). However, controversial observations that the ISDR sequence variation does not account for differences in IFN sensitivity in

patients (9) and also in an HCV subgenomic RNA replicon system (15) have been made. Moreover, the expression of NS5A or the entire HCV polyprotein has been reported to counteract the antiviral effect of IFN in a PKR- and ISDR-independent manner (12). Therefore, the possibility remains that a molecule other than PKR may be involved in the NS5A-mediated inhibition of IFN (50). Restoration of the phosphorylation of STAT1 in cells expressing a deletion mutant lacking ISDR in response to IFN- $\alpha$  and that of PKR phosphorylation upon infection with VSV in cells expressing NS5A mutants lacking amino acid residues 240 to 280 (ISDR) or 280 to 300 may support the hypothesis that the ISDR and the adjacent region are involved in IFN sensitivity. Thus, the ISDR may participate not only in conferring IFN resistance but also in disrupting TLR-MyD88 signaling pathways in macrophage cells.

Several viral proteins have been shown to counteract TLRs and their downstream signaling cascade. The vaccinia virus A46R protein contains a Toll/IL-1 receptor domain that interacts with multiple Toll/IL-1 receptor-containing adaptor molecules, thereby inhibiting the activation of NF- $\kappa$ B and IRF3 (49). Measles virus and respiratory syncytial virus have been shown to inhibit the TLR7- and TLR9-dependent IFN-inducing pathways stimulated by R848 and CpG oligodeoxynucleotides in primary human pDCs (45). HCV NS3/4A has been shown to influence the functions of adaptor molecules mediating TLR-dependent and -independent signaling pathways, resulting in an impairment of the induction of IFN- $\beta$  as well as the subsequent IFN-inducible genes (11). Recently, RIG-I and MDA5 have been identified as being cytoplasmic dsRNA detectors responding to viral RNAs and poly(I:C) in a TLR-independent manner and recruit IPS-1 as an adaptor molecule for signal transduction (24). The uncapped 5'-triphosphate RNA generated by viral polymerases was shown to be selectively recognized by RIG-I (18, 39). In this study, we could demonstrate that the invasion of VSV and poly(I:C) into RAW cell lines is preferentially recognized by RIG-I-IPS-1- and TLR3-TRIF-dependent signaling pathways, respectively, and that the expression of HCV NS3/4A protease selectively inhibits cytokine production upon infection with VSV through the cleavage of IPS-1. Therefore, it is feasible that the expression of NS5A and NS3/4A proteins in macrophage cells may disrupt TLR-dependent and -independent signaling pathways, respectively. However, the mechanism for the inhibition of the TLR signaling pathway in the macrophage cells by the expression of NS3 or NS4B remains unclear.

Although there have been reports suggesting a lack of DC dysfunction in both chimpanzees and humans chronically infected with HCV (26, 32), direct infection of DCs with HCV may be a plausible mechanism for the dysfunction of DCs in patients with chronic HCV infection (4, 21). Indeed, the HCV genome has been detected in DCs by PCR (4), and HCV was detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells from patients with chronic HCV infection (5). Further experiments are needed to exclude the possibility of contamination of viral RNA in blood samples. Pseudotype VSV-bearing chimeric HCV E1 and E2 proteins have been shown to infect immature myeloid DCs isolated from healthy donors through interactions with lectins in a Ca-independent manner (20). Recently, the *in vitro* replication